A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination with Other Anticancer Agents in Participants with Solid Tumors (eVOLVE-01)
Sunway Medical Centre Penang
PRINCIPAL INVESTIGATOR
Dr. Ho Kean Fatt
Email: hokf@sunmed.com.my
Tel: 04-373 5918
CONTACT
Tel: 04-373 8097
SC: Chooi Chin Ying
Email : chooicy@sunway.com.my
Sub-investigator:
(1) Dr. Cheah Soon Keat
Email: cheahsk@sunmed.com.my
Tel: 04-373 5916
(2) Dr. Doris Chow Sze Ying
Email: doriscsy@sunmed.com.my
Tel: 04-373 5913
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the CDK4 Inhibitor BGB-43395, Alone or as Part of Combination Therapies in Patients With Metastatic HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced Solid Tumours
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
SUHANA BINTI YUSAK
CONTACT
SC: Shamiza binti Ahmad Shaharudin
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
CHOONG SWEE HSIA
CONTACT
SC: Nur Adilah Abdul Aziz
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Fong Yian Ching
A Phase I, Multicenter, Open-label, First-in Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Tumors (EGRET)
Advanced Solid Tumours
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Erfan Bin Salbi, Lim Li Fang
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRAS G12C Mutant Solid Tumors
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
SC: Angelyna Michelle
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
Facebook